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 Abstract 26 
Atrogin-1 is a conserved ubiquitin E3 ligase that is central to the early stages of skeletal and 27 
cardiac muscle wasting and degradation following starvation and inflammatory diseases.  The 28 
control of protein turnover is different between endothermic and ectothermic animals 29 
reflecting the body energy requirements.  Here we have characterised the promoter of the 30 
atrogin-1 gene in a phylogenetically diverse group of vertebrates and show conserved FOXO 31 
elements are present in all species examined. We have examined the gene expression 32 
responses in primary muscle cell culture to key immune modulators (IL-1β, interferon type 1 33 
and interferon γ) and to the anabolic hormone insulin like growth factor (IGF-1). We show 34 
that the IL-1β and interferon type 1 increased atrogin-1 mRNA expression whereas IGF-1 35 
suppressed atrogin-1 expression. The proximal promoter of salmon atrogin-1 was used to 36 
transfect primary muscle cell cultures and we found all three cytokines increased promoter 37 
activity whereas there was a decrease caused by IGF-1 exposure. We hypothesise that the 38 
main drivers for atrogin-1 expression are via the conserved FOXO site, but other transcription 39 
binding sites such as NFκΒ, STAT and IRFs may also be involved in a synergistic manner 40 
following immune stimulation when free amino acids need to be released for muscle protein 41 
reserves.   42 
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 Introduction 43 
Skeletal muscle is the largest body protein reserve and is under dynamic regulation to 44 
control the rate protein of deposition and degradation. Muscle atrophy occurs during fasting 45 
and in a variety of diseases such as sepsis, cancer and chronic viral infection (Hasselgren et 46 
al., 2005; Lecker et al., 2006; Gonnella et al., 2011). Loss of muscle mass occurs by both 47 
increased protein breakdown and decrease in protein synthesis. There are three key pathways 48 
of protein degradation, these include lysosomal proteases, calpains and the ubiquitin 49 
proteasome route of protein degradation (Ubp). In muscle tissue the Ubp is responsible for 50 
the vast majority of protein turnover (Mitch & Goldberg, 1996; Gomes et al., 2001). The Ubp 51 
has also been shown to be involved in increased protein degradation during muscle atrophy in 52 
fish as in mammals (Seiliez et al., 2008; Tacchi et al., 2011; Fuentes et al., 2012). During the 53 
Ubp pathway proteins are targeted for destruction by the proteasome, three enzymatic 54 
components are required to link chains of ubiquitin monomers onto proteins which targets 55 
them for degradation in the proteasome (Glickman & Ciechanover, 2002) and subsequent 56 
release of peptides and free amino acids that can either be used for recycling or further 57 
oxidation and gluconeogenesis (Fuentes et al., 2012). E1 (Ub-activating enzyme) and E2s 58 
(Ub-carrier proteins) prepare ubiquitin for conjugation but the key enzyme in the process is 59 
the E3 (Ub–protein ligase) (Bonaldo and Sandri, 2013; Lecker et al., 2006) which confers 60 
specificity to the system. E3 ubiquitin ligases are now recognised as an extended family of 61 
proteins that regulate many different cellular processes (Berndsen and Wolberger 2014).  62 
Atrogin-1 has been identified as a key ubiquitin E3 ligase, a protein central in 63 
regulation of skeletal muscle mass in both mammals (Gomes et al., 2001) and fish (Tacchi et 64 
al., 2010, Bower et al., 2010, Cleveland et al 2010). In mammals the expression of atrogin-1 65 
is suppressed by growth factors such as IGF-1 and insulin via a mechanism involving the 66 
AKT/FOXO transcription factor and AKT/mTOR pathways (Tesseraud et al., 2007).  When 67 
transcriptional suppression is released atrogin-1 expression is increased and results in atrophy 68 
in the muscle tissue. During viral and bacterial infection the control of protein deposition is 69 
altered, most likely to release amino acids for synthesis of immune related genes or for 70 
gluconeogenesis. Viral infection triggers interferon (IFN) production, which activates 71 
targeted genes enabling the host to prevent further viral replication and induce an antiviral 72 
state (Robertsen, 2006; Berg et al., 2009; Zou & Secombes, 2011). IFN type-1 is one of the 73 
main innate antiviral cytokines and is essential for eliciting an effective immune response to 74 
viral infection whereas IFN-γ is involved with the development of the acquired immune 75 
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 response. During both bacterial and viral infections IL-1β is released as a major 76 
proinflammatory cytokine and induces a large number of responsive genes via conserved 77 
signalling pathways often via adaptor molecules such as MyD88 and the transcription factor 78 
NFκB. In fish atrogin-1 responds to both starvation (Bower et al., 2010; Cleveland and 79 
Evenhuis 2010) and the immune response (Tacchi et al., 2010) by increasing in expression. 80 
However, the regulation of this response has not been examined in lower vertebrates, as these 81 
animals will have different energy requirements than endothermic mammals.  82 
In this paper we have characterised the proximal promoter of the Atlantic salmon 83 
(Salmo salar) atrogin-1 gene and identified evolutionary conserved transcription factor 84 
binding sites, we have also examined the promoter activity in primary muscle cell culture.  85 
Transfected primary myocytes with an atrogin-1 luciferase reporter construct were stimulated 86 
with salmonid recombinant cytokines IFN type 1, IFN-γ and IL-1β, in parallel we also used 87 
recombinant salmon IGF-1 as an anabolic hormone. We show that the immune regulating 88 
cytokines increased atrogin-1 activity whereas IGF-1 has a suppressive effect on the atrogin-1 89 
gene. 90 
  91 
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 Materials and methods 92 
Sequence identification, analysis and generation of reporter plasmid 93 
The proximal promoter of the Atlantic salmon atrogin-1 gene was identified following a 94 
BlastN search of the Atlantic salmon genome using the salmon atrogin-1 cDNA sequence 95 
(accession number, NM_001185027.1) as query. A contig sequence (accession number, 96 
AGKD00000000.3, contig AGKD03111157.1) was identified that had 100% identity of the 97 
query sequence.  This sequence was analysed for the putative promoter and the transcription 98 
start sites. DNA repeats present in the sequence were analysed by DNA Repeats Finder 99 
(Benson, 1999) (http://tandem.bu.edu/trf/trf.html). The DNA regulatory sequence motifs 100 
were predicted by the Genomatix Software tools “common TFs” and “Matbase TFs” 101 
(Cartharius et al., 2005 PMID: 15860560).  For comparison to other species the flanking 102 
regions were obtained from species with published genomes from Ensemble. 103 
 Salmon genomic DNA was extracted from muscle tissue using a genomic extraction 104 
kit (Promega). To clone the proximal promoter, primers were designed that included 105 
restriction enzyme sites to allow for directional cloning (Table 1).  PCR was performed using 106 
salmon genomic DNA (20 ng) as template with 2500 U/µl of Taq DNA polymerase (BioTaq, 107 
Bioline), 50 µM of each dNTP and 200 nM of each primer in a final volume of 50 µl. The 108 
cycling protocol was: initial denaturation of 94 ºC for 5 min; 35 cycles of 94 ºC for 30 s, 55 109 
ºC for 30 s and 72 ºC for 30 s; with a final extension of 72 ºC for 5 min. Ten µl of the PCR 110 
product was separated on a 2% agarose gel, stained with web green (Genetics) and analysed 111 
in a UV image analysis system. PCR products were digested with the appropriate restriction 112 
enzymes, Kpn I and Xho I (Promega), for 1 h at 37 ºC, following the manufacturer’s 113 
instructions, and purified using a PCR Purification Kit (Invitrogen). The purified PCR 114 
products were ligated into pre-digested pGL4.10 luciferase reporter vector (Promega), using 115 
T4 DNA ligase (Promega) at 4 ºC overnight, the ligation reaction was used to transformation 116 
of E. coli TAM1 cells (Active Motif, Belgium) following the manufacturer’s instructions. 117 
The plasmid insert sequence was confirmed by PCR using pGL4 RV primer 3 (Promega). 118 
Plasmids were purified from overnight bacterial cultures using an Endotoxin Free Plasmid 119 
Maxi Kit (Qiagen). Plasmid concentrations were determined by spectrophotometry using a 120 
nanodrop machine (Labtech International) and stored at -20 oC. 121 
 122 
Expression and purification of recombinant salmon IGF-1 (saIGF1) 123 
The putative mature peptide of the Atlantic salmon (saIGF-1) (GenBank accession number: 124 
NP_001117095.1) was predicted by the SignalP:4.0 (Petersen et al., 2011). The cDNA 125 
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 fragment encoding the mature peptide saIGF-1 was amplified with primers F1 and R1 (Table 126 
1) by PCR as described above and subcloned into the Bam HI and Hind III sites of pQE30 127 
expression vector (Qiagen). The resultant plasmid was sequenced to confirm the open reading 128 
frame and transformed into the E. coli. JM109 cells (Promega). Induction and purification of 129 
the recombinant proteins under native conditions were performed as described previously 130 
(Hong et al., 2001). To eliminate the potential contamination of bacterial endotoxins such as 131 
LPS, the purified recombinant protein was loaded onto a polymyxin B column (Sigma-132 
Aldrich) and the collected samples were stored at -80°C before use. The purified recombinant 133 
saIGF-1 was analysed by a 4 –12% precast SDS-PAGE gel (Invitrogen Life Technologies) 134 
stained with Brilliant Blue G (Sigma-Aldrich) (Fig. S1), and the concentration measured by 135 
comparison of the protein band density with a standard protein (trypsin inhibitor; Sigma-136 
Aldrich) in the same SDS-PAGE gel using an Ultra Violet Products gel imaging system and 137 
Image Quant TL ver. 3.0 software.  To confirm the activity of the saIGF-1 a dose response of 138 
the recombinant protein was used to examine the expression of atrogin-1 mRNA which is 139 
known to be negatively regulated by IGF-1. A dose response is shown in Fig. S2 which 140 
shows a significant response at IGF-1 concentrations >40 ng/ml. 141 
 142 
RNA extraction and real time PCR 143 
Total RNA was extracted from primary muscle cell culture by lysis in Tri Reagent (1 ml) 144 
(Invitrogen), followed by addition of 200 µl of chloroform and vortexing. The aqueous phase 145 
(RNA) separated by centrifugation (15 min, 13,000 g at 4 oC) was precipitated with equal 146 
volume of isopropanol. The RNA pellet was washed twice with 500 µl 80% ethanol, dried 147 
and resuspended in RNase / DNase free H2O (Sigma). Total RNA concentration was 148 
determined by spectrophotometry (Nano drop) and RNA integrity determined by Agilent 149 
bioanalyser 2100. The RNA was kept frozen at -80 oC until use.  For gene expression studies 150 
complementary DNA (cDNA) was synthesised from 1 µg total RNA. RNA was denatured at 151 
70 oC for 5 min in the presence of 1 µl of Oligo dT17 (500 ng/μl) and RNase free water in a 152 
total volume of 11 µl, and cooled at room temperature for 5 min. The first strand cDNA was 153 
synthesized by adding 1 μl of Bioscript reverse transcriptase (200 U/µl, Bioline), 5 μl of 5x 154 
Bioscript reaction buffer, 1 μl of dNTP (10 mM each) and 7 μl RNase free H2O and 155 
incubated at 42 oC for 1.5 h. The cDNA was diluted to a final volume of 50 μl of 156 
RNase/DNase free H2O (Sigma) and stored at -20 oC. Real time PCR was performed using 3 157 
μl of cDNA template, 2 μl of primers (each 10 µM) (Table1), 10 μl of 2x iQ SYBR Green 158 
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 supermix (Bio-Rad) and 5 μl RNase/DNase free water. Real time PCR amplifications were 159 
performed in white 96 well sealed plates with the following program: initial denaturation at 160 
95 oC for 5 min, then 40 cycles of 95 oC for 5 sec, 55 oC for 30 sec, 72 oC for 30 sec, 78 oC 161 
for 5 sec. The melting curve was checked by fluorescence reading from 79 oC to 94 oC, to 162 
confirm that a single product was amplified. Three housekeeping genes were used for 163 
normalization, including elongation factor 1-α (EF1-α), hypoxanthine phosphoribosyl 164 
transferase 1 (HPRT1) and β-actin.  The real time PCR was carried out with 3 biological 165 
replicates.  A dilution series of cDNA (1x, 10 x, 100 x and 1000 x) was made to determine 166 
the efficiency of primers. The expression of genes was normalized to the mean arbitrary units 167 
of the three housekeeping genes for statistical analysis. 168 
 169 
Primary muscle cell culture and stimulation by cytokines and IGF-1 170 
Atlantic salmon (approximately 25 g) were maintained in the aquarium facility at University 171 
of Aberdeen, UK, under the national ethical guidelines. Fish were kept in fresh water and fed 172 
a commercial diet at 1.5% body weight per day and fish were killed using the schedule one 173 
method. Muscle tissue (above the mid line of the fish) was removed sterilely with a scalpel 174 
and forceps. Primary muscle cell cultures were performed as previously described (Pooley et 175 
al., 2013).  The isolated primary muscle cells were cultured in L15 medium supplemented 176 
with 10% (v/v) foetal calf serum (FCS, Labtech International), and P/S.  Cells were 177 
maintained for 7 days in a 12 well plates (NuncTM) at 22 ◦C until 80% confluence. Cells 178 
were either used for direct stimulation or were transfected. Cells were stimulated with 179 
recombinant salmonid cytokines IFN-γ (Zou et al, 2005), IFN-1 (Zou et al, 2007), IL-1β 180 
(Hong et al, 2001), and recombinant Atlantic salmon IGF-1 and maintained for either 6 h 181 
(IGF-1) or 24 h (cytokines) before RNA extraction.  The times for stimulations were based on 182 
previous findings for cytokines (Martin et al. 2007a, 2007b) and for IGF-1 (Cleveland and 183 
Weber 2010). 184 
 185 
Transfection of primary muscle cell cultures 186 
To confirm the transfection efficiency prior to performing promoter analysis, cells (2x106) 187 
were transfected with 3 μg pTurbo-GFP (Evrogen) using lipofectamine (Life technologies). 188 
FACS analysis was performed to determine the efficiency of transfection of the primary 189 
muscle cells.  For this, following transfection, cells were detached with trypsin and counted 190 
with Trypan blue and 106 cells were pelleted by centrifugation for 5 min at 250 g. Cells were 191 
resuspended in 250 µl of immunofluorescence medium (0.05% sodium azide + 2% FCS) 192 
7 
 
 before incubation for 30 min at 4 oC. Finally cells were centrifuged for 5 min at 250 g and 193 
supernatant was removed. One hundred µl of immunofluorescence medium was added to the 194 
cell pellet before reading. A FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA, 195 
USA) was used to measure the proportion of cells expressing GFP protein. The data were 196 
analysed using FACSDiva software (Becton Dickinson). For the atrogin-1 promoter assay, a 197 
similar transfection assay was performed with 2.5 μg of the reporter plasmid and 0.5 μg of 198 
the internal control reporter vector pRL-TK by using lipofectamine for each well. Cells were 199 
incubated overnight at 22 ◦C. At 24 h post-transfection, cells were stimulated with IL-1β, 200 
IFN-1, IFN-γ or IGF-1. . Following 6 or 24 h the cells were harvested for luciferase reporter 201 
activity (Castro et al., 2010). Three replicate wells were used for each experiment and each 202 
well measured three times. For transfection analysis both firefly and Renilla luciferase 203 
activities were measured using the Dual Luciferase Reporter assay system (Promega). 204 
Atrogin-1 firefly luciferase activity was normalized to Renilla luciferase activity and 205 
expressed as fold change (mean ± se) by comparison between the promoter plasmid 206 
transfected cells with control cells transfected with the Renilla plasmid. Each set of 207 
experiments was repeated three times using the same protocol. 208 
 209 
Statistics 210 
Data were analysed by t-test and all analysis was performed using IBM SPSS statistic 211 
21software package. Differences between means were considered significant if the P value 212 
was <0.05.  213 
 214 
Results  215 
Atrogin-1 gene promoter analysis cloning and sequence analysis 216 
The blastN search of the Atlantic salmon genome (NCBI version releaseAGKD00000000.3) 217 
identified a contig (accession number, AGKD03111157.1) 8185bp in length which contained 218 
the first 4 exons of the atrogin-1 gene and the putative promoter sequence.  Sequence 219 
alignment of the contig sequence (reverse complement sequence) with the reported mRNA 220 
sequence (accession number, GU456729.1) revealed an upstream region of beyond the 221 
transcription start site of 3153 bp, this region was composed of 5’ flanking DNA and also a 222 
number of repeat elements until the end of the contig. The promoter region contained a 223 
predicted TATA box located 57 bp upstream of the start of mRNA transcript and two DNA 224 
repeat sequences, one with 25 copies of CATAACACATCACATCATAACACAT followed 225 
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 by 103 copies of GA and then repeating GAAGTGTACATTTGACTGG to the end of the 226 
sequence. Therefore, in this study we used non repeating 590 bp region of the 5’ flanking 227 
DNA as proximal promoter region for further analysis. The atrogin-1 gene proximal promoter 228 
region was analysed for transcription factor binding sites using Genomatix Software. This 229 
revealed a number of highly conserved sites that may be involved in regulation of gene 230 
transcription (Fig.1). The promoter region contained several well conserved transcription 231 
factor binding sites, these included a highly conserved FOXO site that was located 51 bp 232 
upstream of the predicted transcription start site, other conserved sites include a TATA box at 233 
-23 bp and several forkhead binding sites as represented by FOXP1 (3 elements), FOXJ and 234 
FHXB. We also found several TF binding sites associated with inflammatory and interferon 235 
responses including several STAT binding sites which can be defined as gamma interferon 236 
activated sites (GAS) and interferon regulatory factor binding elements (IRF). Also present 237 
was a conserved NFκB site. When the promoter sequence and predicted transcription factor 238 
binding sites were compared across other vertebrate atrogin-1 proximal promoters we find a 239 
highly conserved location of the FOXO site in all species examined (Fig 2a.).  In all the fish 240 
and the amphibian the conserved sequence is GATAACA, with the mammals having a single 241 
bases change at the 5’ base, which is recognised as being a FOXO element.  In all the species 242 
there is also a CEBP site located at -122 bp from the transcription start site (TSS) in salmon, 243 
in all species these two sites are 10-20bp apart and in the same orientation. All the species 244 
examined have varying numbers of forkhead binding sites, STAT elements and most have at 245 
least one IRF site, the position of these is conserved between Atlantic salmon and rainbow 246 
trout, but there is no detectable conservation of location between the more distantly related 247 
species. 248 
Atrogin-1 mRNA responses to cytokine and IGF-1 stimulation 249 
Our next step was to examine the gene expression response of the salmon primary muscle 250 
cells to the recombinant proteins.  The initial part of this was to validate the response of genes 251 
known to respond to the cytokines or IGF-1 in other cell types as confirmation of 252 
responsiveness in our primary muscle cell system. For saIGF-1 activity, expression of IGF-1 253 
mRNA was examined as a negative feedback, we found that concentrations of 50 and 200 ng 254 
of the recombinant protein significantly reduced IGF-1 mRNA expression. For activity of IL-255 
1β we chose to use IGF binding protein 6 (IGFBP6) previously shown to be highly 256 
responsive to IL-1β in salmon muscle cells (Pooley et al 2013), this gene was highly 257 
increased in expression in response to the IL-1β.  For the interferons, the classically 258 
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 responsive genes Mx and chemokine CXCL11_L1 were used to assess response to IFN-1 and 259 
IFN-γ respectively (Fig. 3) showing large increases in expression 24 h following stimulation.  260 
Following confirmation of the response in the muscle cells to our recombinant 261 
proteins we examined the expression of the atrogin-1 mRNA following the same stimulation. 262 
Atrogin-1 mRNA expression was significantly decreased following 6 h saIGF-1 exposure but 263 
not 24 h (data not shown), whereas both IL-1β and IFN-1 resulted in an increase in atrogin-1 264 
gene expression following 24 h, however we did not detect a significant change in expression 265 
in response to IFN-γ (Fig. 4). 266 
 267 
Analysis of atrogin-1 gene promoter in primary muscle cell culture 268 
To initiate the transfection studies, preliminary experiments were performed with a control 269 
plasmid to determine the transfection efficiency as there are few protocols for transfection 270 
into primary myocytes.  Our protocol showed we obtained approximately 20% transfection 271 
efficiency when the pturboGFP plasmid was used (Fig. S3).  272 
To examine the luciferase activity of the atrogin-1 promoter construct transfected 273 
cells were cultured for under similar regime as for gene expression studies. All three 274 
cytokines induce a significant increase in luciferease activity driven by the atrogin-1 275 
promoter, however the response is only significant at the higher recombinant protein 276 
concentrations (200 ng/ml  for IL-1β and 80 ng/ml  for both interferons). The saIGF-1 277 
resulted in a small decrease in activity compared to the unstimulated control (Fig. 5). 278 
  279 
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 Discussion  280 
The Atlantic salmon atrogin-1 promoter was used to examine the regulation of this key gene 281 
that can be regarded as a marker for catabolic activity in muscle tissue. The proximal 282 
promoter was identified from the Atlantic salmon genome and used as a starting point to 283 
generate a luciferase reporter plasmid. The plasmid was used for transfections using primary 284 
muscle cell cultures, following this the cells were exposed to three key cytokines, IL-1β, 285 
IFN-1, and IFN-γ and, in addition the cells were stimulated with IGF-1 which is a well 286 
characterised anabolic hormone. We showed that the three cytokines increased luciferase 287 
activity following 24 h exposure whereas the IGF-1 caused a marginal decrease in reporter 288 
assay compared to control.  Gene expression of atrogin-1 was increased by IL-1β and IFN-1, 289 
but was unaffected by IFN-γ, whilst IGF-1 resulted in a large decrease in atrogin–1 mRNA 290 
expression. Although the mRNA levels were not significantly increased by the IFN-γ 291 
stimulation we did find an increase in the reporter assay. This potentially could be a reflection 292 
of the dynamics of the IFN-γ response and could be with either mRNA / protein turnover or 293 
due to the presence of negative regulator elements in the upstream region of the atrogin-1 294 
promoter analysed in the present study. The control of atrogin-1 expression will help explain 295 
the interactions between immune stimulation and anabolic signals. The cytokines used in the 296 
experiments are all salmonid recombinant proteins and have been previously characterised 297 
(Zou et al., 2005, 2007 and Hogen et al., 2001) whereas we produced the salmon IGF-1 as a 298 
recombinant protein during this work and confirm its activity by the effect on atrogin-1 gene 299 
expression as has previously been shown in mammals (Sandri et al., 2004).  300 
Rapid muscle protein loss occurs in mammals under a variety of physiological 301 
circumstances including sepsis (Lecker et al., 1999), cancer cachexia (Evans et al., 2008; 302 
Tisdale, 2009), and starvation (Lecker et al., 1999; Jagoe and Goldberg, 2001), with the 303 
animal releasing amino acids from the muscle protein stores. The regulation of these 304 
biological processes is becoming more understood and a number of key factors regulate the 305 
reallocation of energy stores during transition from normal to immune response (Lochmiller, 306 
2000). During infection especially an inflammatory response, an acute phase response occurs, 307 
during this time cytokines are responsible for reprogramming the transcriptional activity of 308 
the liver to produce high levels of acute phase reactants such as complement and serum 309 
amyloid proteins.  In parallel, muscle tissue proteins are broken down by controlled 310 
proteolysis to provide amino acid substrates for protein synthesis in the liver. In mammals 311 
this occurs rapidly within 24 h (Bonaldo and Sandri, 2013), and believed to be driven by IL-312 
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 1β and TNFα, however the action within the muscle tissue is not fully elucidated as yet. It is 313 
hypothesised that signalling targeting genes such as atrogin-1 which identifies specific 314 
proteins to be ubiquitinated and destroyed by the proteasome. During cancer cachexia, where 315 
there is sustained muscle mass loss TNFα is believed to be a principal driver of proteolysis 316 
(Donohoe et al., 2011). On the converse, during periods of anabolic growth and rapid 317 
deposition of muscle mass atrogin -1 expression is very low, indicating little protein 318 
degradation / turnover (Nakashima et al., 2006 and 2013). 319 
During anabolic growth there is a decrease in Ubp pathways and is regulated by the 320 
growth hormone/ IGF system.  In fish the dynamics of the response is slower than in 321 
mammals probably as a result of the energy requirements of ectotherms compared to warm 322 
blooded mammals. A number of recent reports have described how atrogin-1 is altered during 323 
starvation (Tacchi et al., 2012), hormonal (Cleveland and Weber., 2010) and viral infection 324 
(Heidari et al 2015) in salmonids, however these papers have not examined the promoter 325 
region of the gene and speculated on the regulatory control. 326 
The promoter used in this paper was identified from the recently released salmon 327 
genome, a single contig (8185bp) contained the 5’ end of the gene including 590 bp upstream 328 
flanking DNA from the transcription start site. Upstream of this 590 bp was a series of repeat 329 
sequences (>1800bp) that continued to the very end of the assembled contig, we made several 330 
unsuccessful attempts to walk along the flanking DNA by cloning approaches (Castro et al., 331 
2008), in case the repeat was a sequencing artefact. We also observed in the closely related 332 
rainbow trout genome that the atrogin-1 promoter was at the end of a contig, most potentially 333 
because it too had a repeating element.  From this we concluded the proximal promoter may 334 
have most of the key transcription binding factors for gene regulation.  One of the key 335 
transcription factors controlling protein synthesis and degradation are members of the 336 
forkhead transcription factors, especially the FOXO family and are regarded as central to the 337 
regulation of muscle atrophy.  In mammals the FOXO transcription factors are increased in 338 
parallel to catabolic stimuli (Sandri et al., 2004) and transfection of FOXO transcription 339 
factors results in increased expression of atrogin-1 mRNA (Mcloughlin et al., 2009). Akt 340 
signals negatively regulate FOXO by phosphorylating them and promoting export to the 341 
cytoplasm and thus preventing binding to gene promoters. The IGF/Akt/mTOR pathway 342 
enhances anabolic muscle phenotype and decreases protein degradation, this pathway also 343 
phosphorylates the FOXO protein. Catabolic signals result in dephosphorylation of FOXO 344 
and translocation to the nucleus and activation of target genes.  We carried out in silico 345 
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 analysis of common TF binding sites for several teleosts, amphibian and mammals and show 346 
that a conserved FOXO site is located within 400 bp of the translation start site.  The 347 
consensus sequence for FOXO is D(T/A/G)R(G/A)W(T/A)M(A/C)AACA we find this TF binding 348 
site in all the promoters we examined with the most common sequence of GATAAACA 349 
which is completely conserved for all teleosts and the amphibian Xenopus. In Atlantic 350 
salmon and rainbow trout there are three other closely conserved sites but do not fully adhere 351 
to the consensus sequence.  It is of interest that this conserved FOXO site is consistently 3’ 352 
(within 50 bp) to a conserved CEBP transcription factor binding site, hence it may be that 353 
there is selection to maintain these sites in close proximity. The conservation of the FOXO 354 
site strongly suggests evolutionary selection for its maintenance. This can be further seen as 355 
in mammals there is evidence that both FOXO1 and CEBP are required for expression of 356 
genes involved in gluconeogenesis such as G6Pase and PEPCK, with promoter elements for 357 
both FOXO and CEBP being required for promoter activity of these genes (reviewed by 358 
Gross et al., 2008), suggesting these promoter element positions may be conserved across 359 
other genes. 360 
In addition to the forkhead binding sites we also found other TF binding sites that are 361 
often targeted following immune activation following viral and bacterial infection.  362 
Specifically we find NFκB binding sites in most of the species, these are the final effectors 363 
following cytokine and toll like receptor activation that occurs via intermediates such as 364 
MyD88 and TRAF 6 (Bonaldo and Sandri, 2013) which could be an additional mechanism by 365 
which the proinflammatory cytokine IL-1β regulates atrogin-1. Interferon regulatory factor 366 
binding sites are found in the teleost and Xenopus flanking regions and could contribute to 367 
regulation by the interferon molecules. Finally we found STAT binding sites, these often 368 
represent binding elements for IFN-γ and for interferon gamma activated sequences (GAS) 369 
that are highly conserved and key regulatory sites for responses in salmonid fish (Castro et 370 
al., 2008 and 2010). The positioning of these TFs is not as conserved as the FOXO and the 371 
closely linked CEPB site.  So we would hypothesise that the key drivers for expression are 372 
via the FOXO site with additional levels of regulation by other factors directly downstream of 373 
the classic cytokine signalling. 374 
The control of anabolic signalling occurs at different levels. Recent work shows that 375 
IGF binding protein 6 (IGFBP-6) is strongly up regulated in primary muscle cell cultures of 376 
salmon in response to IL-1β (Pooley et al., 2013), so an additional level of control could be 377 
suppression of IGF activity by up regulation of the IGFBP6. Here we show that IGFBP6 378 
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 expression is also increased following IL-1β stimulation, but decreased following IGF-1 379 
stimulation at 50 ng/ml-1. With this in mind additional control could be that the IL-1β 380 
interferes with IGF signalling (i.e. prevents IGF-1 / receptor binding) and hence the PI3K, 381 
AKT/ FOXO pathway resulting in FOXO being de phosphorylated and binding to the 382 
atrogin-1 promoter.  Further work using these models would be required to determine how 383 
the IL-1β affects the atrogin-1 gene.  384 
In conclusion we show that in vertebrates from teleosts to mammals there are 385 
conserved FOXO transcription factor binding sites of the proximal atrogin-1 promoter, in all 386 
cases this site is closely linked to a CEBP binding site. We show that the cytokines IL-1β and 387 
interferons type I and γ all increase atrogin-1 promoter activity whereas IGF-1 stimulation 388 
decreases both gene expression of atrogin-1 and reduces the luciferase reporter activity.  389 
These results add to the growing evidence linking the immune response to the control of 390 
anabolic and catabolic signalling in muscle cells. Further experiments will target specific 391 
sites within the promoter to clarify the regulatory pathways. 392 
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 Figure legends 550 
 551 
Figure 1 552 
Nucleotide sequence of Atlantic salmon atrogin-1 determined from genomic contig 553 
AGKD03111157.1.  The key transcription factor core binding sites as determined by 554 
Genomatrix TF search (Cartharius et al., 2005) are in bold and underlined.  The name of the 555 
TF binding site is above the sequence.  The sequence in grey indicates the beginning of the 556 
repeat units that continue to the end of the sequence contig. The sequence highlighted in 557 
yellow represents the 5’ untranslated region of the mRNA. TSS indicates the transcription 558 
start site and the ATG for translation are both shown by arrows.  559 
 560 
Figure 2 561 
Transcription factor binding sites in the 5’ flanking proximal promoter of atrogin-1 genes 562 
from different vertebrate groups.  All number are given from 1 which represent the ATG 563 
translation start site, this was done as the precise transcription start site is not known for all 564 
the genes.  The sequences were obtained from ensemble for Stickleback 565 
(ENSGACT00000008171), Fugu (ENSTRUG00000005123), Xenpous 566 
(ENSXETG00000023228), Mouse (ENSMUSG00000022358) and Human 567 
(ENSG00000156804).  Rainbow trout promoter was obtained from the rainbow trout genome 568 
and Atlantic salmon from NCBI as described above. 569 
 570 
Figure 3 571 
mRNA expression in primary muscle cell culture of IGFBP-6, MX and CXCL11 in response 572 
to 24h stimulation with (a) IL-1β, (b) IFN-1 (c), IFN-γ, and IGF-1 following 6 h stimulation 573 
with saIGF-1 (d). All genes were normalized to 3 housekeeping genes: ELF-1α, β actin and 574 
HPRT. The expression is presented as arbitrary units with unstimulated control given a value 575 
of 1.00. The bars represent mean ± se (n=3), asterisks indicate a significant response 576 
compared to non-stimulated cells (*p<0.05, **p<0.01 and ***p<0.001).  577 
 578 
Figure 4:  579 
Gene expression response of atrogin-1 to (a) IL-1β, (b) IFN-1, (c) IFN-γ after 24 h and to 580 
IGF-1 (d) following 6h stimulation in primary muscle cell culture. All genes were normalized 581 
to 3 housekeeping genes: ELF1, β actin and HPRT. The expression is presented as arbitrary 582 
units with unstimulated control given a value of 1.00. The bars represent mean ± se (n=3), 583 
asterisks indicate a significant response compared to non-stimulated cells (*p<0.05, **p<0.01 584 
and ***p<0.001). 585 
 586 
Figure 5:  587 
Luciferase production of primary muscle cells transfected with the atrogin-1 reporter 588 
construct and vector containing the Renilla luciferase gene in response to (a) IL-1β, (b) IFN-589 
1, (c) IFN-γ for 24h and  (d) saIGF-1 for 6h. Data are representative of three independent 590 
experiments and show the mean RLU±se. (n= 3). Asterisks indicate a significant response 591 
compared to non-stimulated cells (*p<0.05, **p<0.01 and ***p<0.001). 592 
 593 
Supplementary Figures 594 
Figure S1:  595 
Production and purification of recombinant saIGF-1 from the E. coli. JM109 cells.  Purified 596 
SaIGF-1 protein (300 ng) was separated on a SDS-PAGE gel under denaturing conditions.  597 
 598 
Figure S2: 599 
19 
 
 Does response effect of recombinant saIGF-I on the expression of atrogin-1 mRNA in 600 
primary muscle cells. The cells were incubated with increasing doses of recombinant saIGF-I 601 
(0-200 ng/ml) for 6 h. The expression is presented as arbitrary units and the bars indicated 602 
mean ± se (n=3). Atrogin-1 expression was normalized to 3 housekeeping genes: ELF-1α, β 603 
actin and HPRT. Asterisks indicate a significant response compared to non-stimulated cells 604 
(*p<0.05). 605 
 606 
Figure S3: 607 
A. Efficiency of primary muscle cells transfection as determined by FACS. The images are 608 
representative of two independent experiments. B. Detection of GFP expression was 609 
observed under fluorescence microscopy 24 h after transfected primary muscle cell culture. 610 
 611 
  612 
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 Table 1: Primers used for Atlantic salmon atrogin-1 expression and promoter construction. 
 
Primer name Sequence 5'-3'a Accession Nob  size (bp) c  
 Cloning into pGL4   Atrogin-1_PF GGTACCATTATACCTGGGAAGAAAATACTT 
AGKD03111157.1 590 Atrogin-1_PR CTCGAGTGATGTGTTGTCTGGTATTGTGAC 
 
IGF-1 recombinant protein    sa IGF-1_RF CGCGGATCCGGGCCCGAGACCCTGTGTGG NM_001123623.1 
213 sa IGF-1_RR  CCCAAGCTTTCAAGCTGCCTTGCCAGAC 
 Real time PCR   
EF1-α_QF CAAGGATATCCGTCGTGGCA 
AF321836  327 EF1-α_QR ACAGCGAAACGACCAAGAGG 
β-actin_QF TGACCCAGATCATGTTTGAGACC 
AF012125  146 
β-actin_QR  CTCGTAGATGGGTACTGTGTGGG 
HPRT1_QF  CCGCCTCAAGAGCTACTGTAAT 
EG866745  255 HPRT1_QR GTCTGGAACCTCAAACCCTATG 
CXCL11_QF AAGGCCAAGTGGGGTCATTCTAA 
DR696064 320 CXCL11_QR AACGTATTCAGGCAGTCTTCAGG 
MX_QF TGAGGACTCGGCAGAAAGGATGTA 
U66475.1 415 MX_QR CTTCGCGGATTTCAGGAGGAGGTTAGG 
IFN-γ_QF AGGACACGTTTGAGGACAGTGA 
AJ841811.1 198 IFN-γ_QR CTCAGGTATCCTCTTCAGGA 
IL-1β_QF GCTGGAGAGTGCTGTGGAAGAACATATAG 
AJ223954.1   179 IL-1β_QR CCTGGAGCATCATGGCGTG 
IGF-1_QF CCTGTTCGCTAAATCTCACTT 
EF432852.2 185 IL-1β_QR TACAGCACATCGCACTCTTGA 
IGF-BP6_QF GCTCAATAGTGTTCTGCGTGG 
DQ190459.2 118 IGF-BP6_QR CTTGGAGGAACGACACTGCTT 
Atrogin-1_QF CGAGTGCTTCCAGGAGAATCTG 
GU456729.1  384 Atrogin-1_QR CCATCAAGGAGCTCCTTCAGAC 
 
The restriction sites added to sequence are in italics: aAtrogin-1-KpnI (GGTACC), atrogin-1- 
XhoI (CTCGAG), saIGF- BamHI (GGATCC) and saIGF1-HindIII (CCCAA). bAccession 
number are from NCBI. cProduct size (bp). 
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